Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 vs NVA237 and Tiotropium in Severe to Very Severe COPD
NCT01120691Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations at 64 weeks. Started Apr 2010; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01120691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120691.